Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
FibroBiologics Files 2023 Form 10-K Annual Report | ||
By: PR Newswire Association LLC. - 29 Feb 2024 | Back to overview list |
|
HOUSTON, Feb. 29, 2024 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics") a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials has filed its Annual Report on Form 10-K for the year ended Dec. 31, 2023, with the U.S. Securities and Exchange Commission. The filing can be viewed through a link on FibroBiologics' website at https://ir.fibrobiologics.com/sec-filings/annual-reports. Upon written request, stockholders may receive, free of charge, a paper copy of FibroBiologics' Annual Report on Form 10-K (including complete audited financial statements). Requests should be communicated in writing to FibroBiologics, Attention: Investor Relations, 455 E. Medical Center Blvd, Suite 300, Houston, TX 77598. About FibroBiologics General Inquiries: Investor Relations: Media Contact: View original content to download multimedia:https://www.prnewswire.com/news-releases/fibrobiologics-files-2023-form-10-k-annual-report-302076516.html SOURCE FibroBiologics |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |